Evista is indicated for use by women after menopause to treat and prevent osteoporosis. Additional calcium and vitamin D should be taken with Evista.
Previously, than taking raloxifene will make sure your doctor or pharmacist knows: (далее…)
8.1 Pregnancy
Category X. EVISTA it should not be used in women who are or can become pregnant women [see
Contra-indications (4.2)]. (далее…)
Experience of Clinical tests
As clinical researches are spent under widely variable conditions, the adverse norms of reaction observed in
Clinical tests of a preparation cannot be direct in comparison with norms in clinical tests of other preparation, and cannot
Reflect the norms observed practically. (далее…)
5.4 Preklimaterichesky Use
There is no sign for premenopausal use Raloxifene. Safety EVISTA in premenopausal women
Has not been established also its use it is not recommended. (далее…)
4.1 Venous Tomboembolizm
For EVISTA serve as contra-indication in women with active or background venous thrombemboly (VTE),
Including a deep vein thrombosis pulmonary emboly, and concerning a retina of an eye a vein thrombosis [sees Preventions and
Precautions . (далее…)
2.1 Recommended Dispensing
Recommended dosage - one EVISTA on 60 mg (raloxifene gydrocloride tablets) a tablet daily, which
Any time of day without the relation to food intakes [can cope sees Clinical Pharmacology (12.3)]. (далее…)
1.1 Processing and Prevention Osteoporosis in Concerning the period after menopause Women
Raloxifene it is designated for processing, and prevention osteoporosis in concerning by the period after menopause women.
1.2 Reduction of Risk of the Aggressive Cancer of a mammary gland in Concerning the period after menopausal Women with Osteoporosis
Raloxifeneit is designated for reduction of risk of an aggressive cancer of a mammary gland in concerning the period after menopause women with osteoporosis . (далее…)